Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. (NASDAQ: AEMD) is a clinical-stage medical device innovator advancing the Hemopurifier® - a therapeutic filtration device targeting cancer-enabling exosomes and life-threatening viruses. This page provides investors and medical professionals with essential updates on clinical developments, regulatory progress, and strategic initiatives.
Key resources include press releases detailing trial protocols, ethics committee approvals, and operational milestones. Users will find verified information on oncology applications for treatment-resistant cancers and infectious disease programs, all presented in compliance with financial disclosure standards.
Content highlights encompass FDA communications, trial enrollment updates, and peer-reviewed research collaborations. The curated news collection serves as a reliable reference for tracking the Hemopurifier®'s progress through clinical validation stages and potential therapeutic applications.
Bookmark this page for direct access to Aethlon Medical's official announcements, including breakthrough device designations and international trial expansions. Check regularly for updates on this pioneering approach to blood filtration technology and its implications for cancer immunotherapy advancement.
Aethlon Medical (NASDAQ: AEMD) has published preclinical study results in Transplant Immunology demonstrating new potential applications for its Hemopurifier® blood filtration system in organ transplantation. The study, published February 28, 2025, shows the device's effectiveness in removing harmful extracellular vesicles (EVs) and microRNAs from renal perfusates of discarded donor kidneys.
The research indicates significant reductions in EVs and microRNAs linked to renal dysfunction, suggesting potential benefits for kidney transplant outcomes. This expands the Hemopurifier's therapeutic potential beyond its current applications in virology and oncology, presenting what the company calls a "pipeline within a device."
While the company's primary focus remains on Australian and India Oncology trials, these findings suggest the technology could potentially be integrated with existing organ preservation systems, though further evaluation and clinical trials would be necessary.
Aethlon Medical (NASDAQ: AEMD), a medical therapeutic company developing products for cancer and life-threatening infectious diseases, will present at the Emerging Growth Conference on February 19, 2025. The company's CEO, James Frakes, will deliver a 30-minute presentation starting at 11:25 AM Eastern time.
This interactive online event offers shareholders and the investment community the opportunity to engage directly with Mr. Frakes in real-time. Participants can submit questions in advance to Questions@EmergingGrowth.com or during the live session.
For those unable to attend live, an archived webcast will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel. Registration is required through the provided webcast link to attend and receive updates.
Aethlon Medical (NASDAQ: AEMD) reported its fiscal Q3 2024 results and key developments. The company achieved a significant milestone with the first patient treated in their Hemopurifier® cancer trial in Australia on January 29, 2025. The treatment was completed successfully with no device-related complications.
The company implemented protocol modifications to improve trial efficiency, including changes to patient enrollment criteria and broadening eligibility requirements. Two clinical sites are currently active in Australia, with a third site expected to activate in February 2025.
Financial highlights include a cash balance of $4.8 million as of December 31, 2024. Operating expenses decreased by 50% to $1.8 million compared to $3.6 million in the same quarter last year, primarily due to reduced payroll expenses, professional fees, and general administrative costs. Net loss decreased to $1.8 million from $3.5 million in the prior year period.
Aethlon Medical (Nasdaq: AEMD), a medical therapeutic company developing products for cancer and infectious diseases treatment, has scheduled its fiscal third quarter financial results release for February 12, 2025, at 4:15 p.m. ET.
The company will host a conference call at 4:30 p.m. ET on the same day, featuring management's formal remarks followed by a Q&A session. The call will be accessible through pre-registration or direct dial-in, with replay available until March 12, 2025.
Aethlon Medical (NASDAQ: AEMD) has achieved a significant milestone by treating the first patient with its Hemopurifier device in an Australian clinical trial. The trial focuses on patients with solid tumors who show stable or progressive disease during anti-PD-1 monotherapy treatments like Keytruda® or Opdivo®.
The first patient, who showed disease progression after two months of Nivolumab treatment, received a 4-hour Hemopurifier treatment on January 29, 2025, at the Royal Adelaide Hospital, tolerating the procedure without complications. The trial aims to enroll approximately 18 patients to assess safety, feasibility, and optimal dosing.
The Hemopurifier is designed to remove tumor-derived extracellular vesicles (EVs) from the bloodstream, potentially improving response rates to anti-PD-1 therapies, which currently only benefit 30-40% of patients. The study will evaluate different treatment intervals and analyze changes in EV concentrations to inform future Premarket Approval studies.
Aethlon Medical (NASDAQ: AEMD) has provided an update on its investigational Hemopurifier device's capability to capture H5N1 Bird Flu virus. The update comes amid rising concerns over Bird Flu cases in dairy cows and humans across eight states, including a severe case in Louisiana and California's state of emergency declaration.
Laboratory tests at Battelle labs demonstrated that a miniature version of the Hemopurifier removed 99% of H5N1 after 6 hours of treatment in vitro. The device, which removes enveloped viruses from bloodstream, has been used in 38 patients across 164 treatment sessions for various diseases including hepatitis C, HIV, COVID-19, and Ebola. The Hemopurifier holds FDA 'breakthrough device' designation for life-threatening viruses lacking effective treatments.
Aethlon Medical (NASDAQ: AEMD) reported key developments in its fiscal Q2 2024, including the enrollment of two patients in its Australian clinical trial for the Hemopurifier® device. The trial focuses on treating solid tumor patients who haven't responded to anti-PD-1 therapies. The company has expanded its trial sites, with Pindara Private Hospital now approved for enrollment and a third Australian hospital in the approval process. Additionally, Medanta Medicity Hospital in India received ethics committee approval for a similar trial. The company has implemented cost-cutting measures while maintaining focus on its oncology trials. This comes amid projections showing the solid tumors market is expected to reach $375.4 Billion by 2034.
Aethlon Medical (AEMD) reported fiscal Q2 2024 results and key developments. The company achieved enrollment of first two patients in its Hemopurifier® cancer trial at Royal Adelaide Hospital, Australia. A second site, Pindara Private Hospital, is now open for enrollment. The company received ethics committee approval from Medanta Medicity Hospital in India for a similar trial. Financial highlights include cash balance of $6.9 million and reduced operating expenses to $2.9 million, down 9% year-over-year. Net loss decreased to $2.8 million from $3.0 million in the prior year period. The company implemented cost-cutting measures and appointed James Frakes as permanent CEO.
Aethlon Medical (NASDAQ: AEMD) announced enrollment of its first patient in an Australian clinical trial for the Hemopurifier®, a device designed to combat cancer and viral infections. The trial focuses on patients with solid tumors showing stable or progressive disease during anti-PD-1 therapy. The first patient, enrolled on October 29, 2024, at Royal Adelaide Hospital, will undergo a two-month run-in period receiving anti-PD-1 therapy before potential Hemopurifier treatment. The trial aims to improve upon current 30-40% response rates to anti-PD-1 therapies by removing tumor-produced EVs from the bloodstream. The study will involve 9-18 patients and evaluate safety, feasibility, and optimal treatment intervals.
Aethlon Medical (AEMD) has enrolled the first patient in its Australian clinical trial of the Hemopurifier® at Royal Adelaide Hospital. The trial aims to evaluate safety, feasibility, and dosing in patients with solid tumors who haven't responded to anti-PD-1 therapies like Keytruda® or Opdivo®. The enrolled patient began a two-month run-in period on October 29, 2024, receiving anti-PD-1 therapy.
The trial will include 9-18 patients, focusing on the Hemopurifier's ability to remove tumor-produced Extracellular vesicles (EVs) from bloodstream. Currently, only about 30% of patients respond to anti-PD-1 therapies, and the company hopes to improve these response rates through their treatment.
